Compositions And Methods For Modulating Pro-Inflammatory Immune Response
AssigneesIcahn School of Medicine at Mount Sinai, Board of Regents, The University of Texas System
InventorsShu-Hsia Chen, Chengcheng Zhang, Xunlei Kang, Junke Zheng, Masato Umikawa
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods useful for increasing a pro-inflammatory immune response, treating an autoimmune disorder, inflammation, or transplant rejection in a mammal by activating a leukocyte immunoglobulin-like receptor (LILR) protein. Also provided are compositions and methods useful for increasing a pro-inflammatory immune response, treating cancer, and treating infectious disease in a mammal by blocking the activation of a LILR protein.
Claims46
A composition comprising a leukocyte immunoglobulin-like receptor (LILR) B1 (LILRB1) agonist, LILRB2 agonist, LILRB3 agonist, LILRB4 agonist, or LILRB5 agonist and one or more additional agents selected from the group consisting of:
- a myeloid-derived suppressor cell, a mobilizing agent, a c-jun N-terminal kinase inhibitor, an anti-inflammatory agent, and an immunosuppressive agent.
A composition comprising:
- one or more of an agent that specifically binds to an endogenous Angptl-1 protein, Angptl-2 protein, Angptl-3 protein, Angptl-4 protein, Angptl-5 protein, Angptl-6 protein, Angptl-7 protein, leukocyte immunoglobulin-like receptor (LILR) B1 (LILRB1) protein, LILRB2 protein, LILRB3 protein, LILRB4 protein, or LILRB5 protein;
- an oligonucleotide that decreases the expression of Angptl-1, Angptl-2, Angptl-3, Angptl-4, Angptl-5, Angptl-6, Angptl-7, LILRB1, LILRB2, LILRB3, LILRB4, or LILRB5 mRNA in a mammalian cell;
- and a soluble LILRB1 protein, soluble LILRB2 protein, soluble LILRB3 protein, soluble LILRB4 protein, or soluble LILRB5 protein;
- and
- one or both of a chemotherapeutic agent and an analgesic.
A method of decreasing a pro-inflammatory immune response in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a leukocyte immunoglobulin-like receptor (LILR) B1 (LILRB1) agonist, LILRB2 agonist, LILRB3 agonist, LILRB4 agonist, or LILRB5 agonist.
A method of treating inflammation, an autoimmune disease, or transplant rejection in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a leukocyte immunoglobulin-like receptor (LILR) B1 (LILRB1) agonist, a LILRB2 agonist, LILRB3 agonist, LILRB4 agonist, or LILRB5 agonist.
A method of stimulating a pro-inflammatory immune response in a mammal, the method comprising administering to the mammal a therapeutically effective amount of at least one of an agent that specifically binds to an endogenous angiopoietin-like (Angptl)-1 protein, Angptl-2 protein, Angptl-3 protein, Angptl-4 protein, Angptl-5 protein, Angptl-6 protein, Angptl-7 protein, leukocyte immunoglobulin-like receptor (LILR) B1 (LILRB1) protein, LILRB2 protein, LILRB3 protein, LILRB4 protein, or LILRB5 protein;
- an oligonucleotide that decreases the expression of Angptl-1, Angptl-2, Angptl-3, Angptl-4, Angptl-5, Angptl-6, Angptl-7, LILRB1, LILRB2, LILRB3, LILRB4, or LILRB5 mRNA in a mammalian cell;
- a soluble LILRB1 protein, a soluble LILRB2 protein, a soluble LILRB3 protein, a soluble LILRB4 protein, or a soluble LILRB5 protein.
A method of treating cancer in a mammal, the method comprising administering to the mammal a therapeutically effective amount of at least one of:
- an agent that specifically binds to an endogenous Angptl-1 protein, Angptl-2 protein, Angptl-3 protein, Angptl-4 protein, Angptl-5 protein, Angptl-6 protein, Angptl-7 protein, LILRB1 protein, LILRB2 protein, LILRB3 protein, LILRB4 protein, or LILRB5 protein;
- an oligonucleotide that decreases the expression of Angptl-1, Angptl-2, Angptl-3, Angptl-4, Angptl-5, Angptl-6, Angptl-7, LILRB1, LILRB2, LILRB3, LILRB4, or LILRB5 mRNA in a mammalian cell;
- a soluble LILRB1 protein, a soluble LILRB2 protein, a soluble LILRB3 protein, a soluble LILRB4 protein, or a soluble LILRB5 protein.
The method of claim 39, wherein the inhibitory RNA is a small interfering RNA (siRNA).
A method of identifying a candidate agent for treating an autoimmune disease, inflammation, or transplant rejection in a mammal, the method comprising:
- (a) contacting a leukocyte immunoglobulin-like receptor (LILR) B1 (LILRB1) protein, LILRB2 protein, LILRB3 protein, LILRB4 protein, LILRB5 protein, or a paired immunoglobulin-like receptor B (PIRB) protein with a test agent, and determining the amount of binding of the test agent to the LILRB1 protein, LILRB2 protein, LILRB3 protein, LILRB4 protein, LILRB5 protein, or PIRB protein;
- (b) determining whether the test agent activates LILRB1 protein, LILRB2 protein, LILRB3 protein, LILRB4 protein, LILRB5 protein, or PIRB protein signaling in a cell;
- and
- (c) selecting a test agent that binds to LILRB1 protein, LILRB2 protein, LILRB3 protein, LILRB4 protein, LILRB5 protein, or PIRB protein, and activates LILRB1 protein, LILRB2 protein, LILRB3 protein, LILRB4 protein, LILRB5 protein, or PIRB protein signaling in a cell, respectively, as a candidate agent for treating an autoimmune disease, inflammation, or transplant rejection in a mammal.
A method of identifying a candidate agent useful for treating a cancer in a mammal, the method comprising:
- contacting an angiopoietin-like (Angptl)-1 protein, an Angptl-2 protein, an Angptl-3 protein, an Angptl-4 protein, an Angptl-5 protein, an Angptl-6 protein, or an Angptl-7 protein with a test agent;
- determining whether the test agent binds to the Angptl-1 protein, the Angptl-2 protein, the Angptl-3 protein, the Angptl-4 protein, the Angptl-5 protein, the Angptl-6 protein, or the Angptl-7 protein;
- and
- selecting a test agent that specifically binds to the Angptl-1 protein, the Angptl-2 protein, the Angptl-3 protein, the Angplt-4 protein, the Angptl-5 protein, the Angptl-6 protein, or the Angptl-7 protein as a candidate agent for treating a cancer in a mammal.
Dependencies are inferred from the claim text.